CONCORDBIO: Q3 revenue up 14% YoY, API volumes strong, injectables and CDMO to drive future growth

About this update from Concord Biotech Ltd.

Q3 FY26 saw 14% revenue growth year-over-year, with API volumes driving performance and injectables poised for future growth. Margins were impacted by startup costs, but normalization is expected as new facilities scale. Cash position remains strong, supporting both organic and inorganic expansion.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Concord Biotech Ltd.